Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions
- 13 October 2005
- journal article
- Published by American Society of Hematology in Blood
- Vol. 107 (3) , 1101-1107
- https://doi.org/10.1182/blood-2005-04-1510
Abstract
Decreased major histocompatibility class II (MHCII) expression is associated with poor survival in diffuse large B-cell lymphoma (DLBCL). Immune-privileged site DLBCL (IP-DLBCL) patients reportedly have frequent large deletions at the MHCII locus whereas the mechanism of decreased expression in non-IP-DLBCL is unknown. Gene expression profiling data were used for correlation analyses between expression levels of MHCII genes with each other and their transcriptional regulator, CIITA. Comparative genomic hybridization (CGH) assessed chromosomal alterations at MHCII-related loci. Finally, a map was created of expression of genes that are telomeric, within, or centromeric to the MHCII locus. Correlation coefficients among MHCII genes ranged from 0.73 to 0.92, whereas those between adjacent and intervening genes were lower (-0.12 to 0.49). Correlations between MHCII and CIITA expression were higher (0.53 to 0.60) than between CIITA and neighboring genes (-0.05 to 0.22). In 23 MHCII- cases, CGH detected 2 losses and 2 gains at MHCII loci. Expression of genes telomeric, within, and centromeric to MHCII loci were near normal in most MHCII- cases. Large deletions of the MHCII locus are uncommon in non-IP-DLBCL, implicating altered transcription as the operative mechanism for decreased expression.Keywords
This publication has 27 references indexed in Scilit:
- Clinicopathologic Significance and Prognostic Value of Chromosomal Imbalances in Diffuse Large B-Cell LymphomasJournal of Clinical Oncology, 2004
- Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling ProjectBlood, 2004
- Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six GenesNew England Journal of Medicine, 2004
- A CIITA‐independent pathway that promotes expression of endogenous rather than exogenous peptides in immune‐privileged sitesEuropean Journal of Immunology, 2004
- Inhibition of invariant chain expression in dendritic cells presenting endogenous antigens stimulates CD4+ T-cell responses and tumor immunityBlood, 2003
- Molecular sequelae of histone deacetylase inhibition in human malignant B cellsBlood, 2003
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- Isolation and molecular characterization of spontaneous mutants of lymphoblastoid cells with extended loss of heterozygosityMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1997
- HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma.Journal of Clinical Investigation, 1988
- Bootstrap Methods: Another Look at the JackknifeThe Annals of Statistics, 1979